E001466.Full.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

E001466.Full.Pdf Editorial BMJ Glob Health: first published as 10.1136/bmjgh-2019-001466 on 11 April 2019. Downloaded from WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? Joshua P Vogel, 1,2 Myfanwy Williams,3 Ioannis Gallos,4 Fernando Althabe,1 Olufemi T Oladapo1 To cite: Vogel JP, THE GLOBAL BURDEN OF POSTPARTUM trials of tranexamic acid for PPH treatment Williams M, Gallos I, et al. HAEMORRHAGE and a heat-stable formulation of carbetocin WHO recommendations on 6–12 uterotonics for postpartum Obstetric haemorrhage, especially post- for PPH prevention. The increasing haemorrhage prevention: partum haemorrhage (PPH), was responsible number of PPH prevention and management what works, and which for more than a quarter of the estimated 303 options makes it challenging for providers one?BMJ Glob Health 000 maternal deaths that occurred globally in and health system stakeholders to choose 2019;4:e001466. doi:10.1136/ 2015.1 PPH—commonly defined as a blood where and how to invest limited resources in bmjgh-2019-001466 loss of 500 mL or more within 24 hours after order to optimise health outcomes. birth—affects about 6% of all women giving Multiple uterotonics have been eval- Handling editor Seye Abimbola birth.1 Uterine atony is the most common uated for PPH prevention over the past Received 4 February 2019 cause of PPH, but it can also be caused by four decades, including oxytocin receptor Revised 10 March 2019 genital tract trauma, retained placental tissue agonists (oxytocin and carbetocin), prosta- Accepted 16 March 2019 or maternal bleeding disorders. The majority glandin analogues (misoprostol, sulprostone, of women who experience PPH have no iden- carboprost), ergot alkaloids (such as ergo- tifiable risk factor, meaning that PPH preven- metrine/methylergometrine) and combina- tion programmes rely on universal use of PPH tions of these (oxytocin plus ergometrine, © Author(s) (or their prophylaxis for all women in the immediate or oxytocin plus misoprostol). Trial evidence employer(s)) 2019. Re-use postpartum period. Active management of for each of these options has been meta-an- permitted under CC BY-NC. No the third stage of labour involves prophylactic alysed through multiple separate Cochrane http://gh.bmj.com/ commercial re-use. See rights administration of a uterotonic agent prior to systematic reviews that compared one utero- and permissions. Published by BMJ. delivery of the placenta, as well as delayed tonic option against several other options or 1UNDP/UNFPA/UNICEF/WHO/ cord clamping and controlled traction of the placebo/no treatment. However, subtle but World Bank Special Programme umbilical cord (in settings where skilled birth important methodological differences have of Research, Development attendants are available).2 The uterotonic is emerged between these reviews. For example, and Research Training in the most important component in terms of there are differences in trial eligibility criteria, on September 28, 2021 by guest. Protected copyright. Human Reproduction (HRP), preventing PPH.3 4 In 2012, WHO recom- review outcomes and subgroup comparisons. Department of Reproductive Health and Research, World mended oxytocin (10 IU, intravenously or Some uterotonic comparisons (eg, oxytocin vs Health Organization, Geneva, intramuscularly) as the uterotonic of choice misoprostol) appear in more than one review. Switzerland for PPH prevention at birth for all women.5 Cochrane review standards have evolved over 2 Maternal and Child Health time, meaning more recent reviews may have Program, Burnet Institute, higher methodological rigour. Melbourne, Victoria, Australia 3Cochrane Pregnancy and RECENT INNOVATIONS IN PPH PREVENTION AND These problems were largely resolved Childbirth, University of TREATMENT RESEARCH by a recent Cochrane review and network Liverpool, Liverpool, United There have been major new developments meta-analysis (NMA) of 140 trials (88 947 Kingdom 4 in PPH prevention and treatment in the last women) that considered multiple utero- Institute of Metabolism and tonic drug options (single or combination) Systems Research, University decade, including technological advance- of Birmingham, Birmingham ments (such as inhalational oxytocin and and placebo or no treatment, first published 13 Women's Hospital Foundation the non-pneumatic antishock garment), new in April 2018. A single review of multiple Trust, Birmingham, United treatment strategies (such as advance distri- options meant standardisation of trial eligi- Kingdom bution of prophylactic misoprostol for self-ad- bility, risk of bias assessment and outcome Correspondence to ministration after birth, administration of reporting. The NMA also reported on compar- Dr Joshua P Vogel; oxytocin via Uniiject and care bundles for PPH isons of all options based on the full evidence vogeljo@ who. int management), as well as large multicountry network, providing estimates of effect even Vogel JP, et al. BMJ Glob Health 2019;4:e001466. doi:10.1136/bmjgh-2019-001466 1 BMJ Global Health BMJ Glob Health: first published as 10.1136/bmjgh-2019-001466 on 11 April 2019. Downloaded from Table 1 WHO recommendations on uterotonics for PPH prevention Context Recommendation Efficacy and safety of 1. The use of an effective uterotonic for the prevention of PPH during the third stage of uterotonics for PPH prevention labour is recommended for all births. To effectively prevent PPH, only one of the following uterotonics should be used: ► Oxytocin (recommendation 1.1). ► Carbetocin (recommendation 1.2). ► Misoprostol (recommendation 1.3). ► Ergometrine/methylergometrine (recommendation 1.4). ► Oxytocin and ergometrine fixed dose combination (recommendation 1.5). 1.1 The use of oxytocin (10 IU, IM/IV) is recommended for the prevention of PPH for all births. 1.2 The use of carbetocin (100 µg, IM/IV) is recommended for the prevention of PPH for all births in contexts where its cost is comparable to other effective uterotonics. 1.3 The use of misoprostol (either 400 µg or 600 µg, PO) is recommended for the prevention of PPH for all births. 1.4 The use of ergometrine/methylergometrine (200 µg, IM/IV) is recommended for the prevention of PPH in contexts where hypertensive disorders can be safely excluded prior to its use. 1.5 The use of oxytocin and ergometrine fixed-dose combination (5 IU/500 µg, IM) is recommended for the prevention of PPH in contexts where hypertensive disorders can be safely excluded prior to its use. 1.6 Injectable prostaglandins (carboprost or sulprostone) are not recommended for the prevention of PPH. Choice of uterotonics for PPH 2. In settings where multiple uterotonic options are available, oxytocin (10 IU, IM/IV) is the prevention recommended uterotonic agent for the prevention of PPH for all births. 3. In settings where oxytocin is unavailable (or its quality cannot be guaranteed), the use of other injectable uterotonics (carbetocin, or if appropriate ergometrine/methylergometrine or oxytocin and ergometrine fixed-dose combination) or oral misoprostol is recommended for the prevention of PPH. 4. In settings where skilled health personnel are not present to administer injectable uterotonics, the administration of misoprostol (400 µg or 600 µg PO) by community healthcare workers and lay health workers is recommended for the prevention of PPH. IM, intramuscular; IV, intravenous; PO, per oral; PPH, postpartum haemorrhage. http://gh.bmj.com/ in the absence of a direct comparison (‘head-to-head’) settings where oxytocin is unavailable (or its quality trial. The NMA was closely followed by important new cannot be guaranteed), the use of other injectable utero- findings from a WHO-led, multicountry PPH prevention tonics (carbetocin, or if appropriate ergometrine/meth- trial in June 2018.11 This trial randomised nearly 30 000 ylergometrine or oxytocin and ergometrine fixed-dose on September 28, 2021 by guest. Protected copyright. women in 10 countries to either oxytocin (the recom- combination) or oral misoprostol is recommended for mended standard of care) or a heat-stable formulation the prevention of PPH. In those settings where skilled of carbetocin, and found that heat-stable carbetocin health personnel are not present to administer injectable was non-inferior to oxytocin for the prevention of PPH uterotonics, the administration of misoprostol (400 µg (defined as blood loss of at least 500 mL), and the use or 600 µg orally) by community healthcare workers and of additional uterotonic agents. What should clinicians lay health workers is recommended for the prevention make of these important new findings? It was in this of PPH. context that the Executive Guideline Steering Group on It should be noted that the uterotonic options Maternal and Perinatal Health advised WHO to prioritise containing ergometrine (ergometrine alone, and the updating of its recommendations on uterotonics for 14 oxytocin–ergometrine fixed-dose combination) are PPH prevention. context-specific recommendations, on account of the need to exclude the presence of hypertensive disor- UPDATED WHO RECOMMENDATIONS ON UTEROTONICS FOR ders prior to its use. This condition may limit their use PPH PREVENTION in those settings where there is lack of screening for In December 2018, WHO issued new recommendations hypertensive disorders in pregnancy. WHO also made a on uterotonics for PPH prevention (table 1).15 Oxytocin context-specific recommendation regarding the use of (10 IU, intravenously or intramuscularly) remains the carbetocin for PPH prevention (use
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0311655 A1 Leonard Et Al
    US 20100311655A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0311655 A1 Leonard et al. (43) Pub. Date: Dec. 9, 2010 (54) INTRANASAL CARBETOCIN Related U.S. Application Data FORMULATIONS AND METHODS FOR THE TREATMENT OF AUTISM (60) Provisional application No. 60/942,607, filed on Jun. 7, 2007. (75) Inventors: Alexis Kays Leonard, Maple Valley, WA (US); Joshua O. Publication Classification Sestak, Lawrence, KS (US); Henry R. Costantino, Woodinville, WA (51) Int. Cl. (US); Anthony P. Sileno, A638/II (2006.01) Brookhaven Hamlet, NY (US); A6IP 25/22 (2006.01) Lalit Raj Peddakota, San Diego, A6IP 25/24 (2006.01) CA (US); Kayvon Emile Sharghi, A6IP 25/18 (2006.01) Seattle, WA (US); Garland M. (52) U.S. Cl. ....................................................... 514/11.6 Bellamy, Bothell, WA (US); Jason Philip Gesty, Seattle, WA (US) (57) ABSTRACT Correspondence Address: Methods and compositions containing oxytocin oran oxyto Eckman Basu LLP cin analog. Such as carbetocin, are provided for the prevention 2225 E. Bayshore Road, Suite 200 and treatment of autism spectrum disorders, related disorders Palo Alto, CA 94.303-3220 (US) and symptoms of Such disorders. The methods and composi tions of this disclosure are effective in the treatment of social (73) Assignee: MDRNA, INC. Bothell, WA (US) withdrawal, eye contact avoidance, repetitive behaviors, (21) Appl. No.: 12/599,267 anxiety, attention deficit, hyperactivity, depression, loss of speech, Verbal communication difficulties, aversion to touch, (22) PCT Filed: Sep. 28, 2007 visual difficulties, comprehension difficulties, and Sound and light sensitivity. Additional compositions and methods are (86). PCT No.: PCT/US07f79994 provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent S371 (c)(1), to yield more effective treatment tools against autism spec (2), (4) Date: Jul.
    [Show full text]
  • ( 12 ) United States Patent
    US009566311B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 566 ,311 B2 Siekmann et al. (45 ) Date of Patent: Feb . 14 , 2017 ( 54 ) PHARMACEUTICAL COMPOSITION ( 56 ) References Cited (75 ) Inventors : Britta Siekmann , Lomma ( SE ) ; U . S . PATENT DOCUMENTS Mattias Malm , Copenhagen (DK ) ; 7 ,635 ,473 B2 * 12 /2009 Warne et al. .. .. .. .. 424 / 133 . 1 Anders Nilsson , Copenhagen (DK ) ; 2001/ 0027177 Al 10 / 2001 Woodrow Kazimierz Wisniewski, Copenhagen 2003 /0119728 A1 6 / 2003 Scheidl et al . 2003/ 0138417 A1 7 / 2003 Kaisheva et al. (DK ) 2004/ 0235956 A1 * 11/ 2004 Quay .. .. .. .. .. .. .. 514 /573 ( 73 ) Assignee : Ferring B . V ., Hoofddorp (NL ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this EP 0916347 A15 / 1999 patent is extended or adjusted under 35 EP 2174652 A2 4 / 2010 U . S . C . 154 (b ) by 0 days . WO W09501185 * 1 / 1995 A61K 38 / 11 WO W09501185 A11 / 1995 WO 2004062689 AL 7 /2004 ( 21 ) Appl. No. : 13 /824 , 132 WO WO2008042452 A 4 / 2008 WO WO 2008150305 A1 * 12 /2008 A61K 9 /08 ( 22 ) PCT Filed : Sep . 29 , 2011 WO WO2008150305 Al 12 /2008 WO WO2009122285 * 10 / 2009 .. .. CO7K 7 / 16 ( 86 ) PCT No. : PCT/ IB2011 / 002394 WO WO2009122285 A8 12 / 2009 $ 371 ( c ) ( 1 ), OTHER PUBLICATIONS ( 2 ) , ( 4 ) Date : May 3 , 2013 Remington : The Science and Practice of Pharmacy , Alfonso R . (87 ) PCT Pub. No. : W02012 /042371 Gennaro , Ed ., 20th Edition , 2000 , (only pp . 245, 1690 provided herewith ) . * PCT Pub . Date : Apr. 5 , 2012 Product Monograph Duratocin , Ferring Inc . Mar. 29 , 2006 revi sion. * (65 ) Prior Publication Data Hawe et al .
    [Show full text]
  • DURATOCIN® Vial
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrDURATOCIN® Carbetocin Injection 1 mL vial, 100 mcg / mL Intravenous and intramuscular use Uterotonic Agent Ferring Inc. Date of Initial Approval: 200 Yorkland Boulevard JUN 20, 1997 Suite 500 North York, ON Date of Revision: FEB 21, 2020 M2J 5C1 Submission Control No: 225949 DURATOCIN Page 1 of 25 RECENT MAJOR LABEL CHANGES INDICATIONS FEB 2020 DOSAGE AND ADMINISTRATION FEB 2020 WARNINGS AND PRECAUTIONS, General FEB 2020 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ......................................................................................2 TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4 1 INDICATIONS....................................................................................................................4 1.1 Pediatrics ....................................................................................................................4 1.2 Geriatrics ....................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 3 DOSAGE AND ADMINISTRATION ...............................................................................4 4 OVERDOSAGE .................................................................................................................5
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME PROSTIN 15M 250 microgram (µg)/mL Solution for Injection 2. QUALITATIVE AND QUANTITIATIVE COMPOSITION Each 1 mL contains 250 μg carboprost or 332 μg carboprost (as tromethamine). Excipient(s) with known effect Each 1 mL contains 9.45 mg/mL benzyl alcohol (added as preservative). For the full list of excipients, see section 6.1. 3. PHARMACEUTIAL FORM Solution for Injection. PROSTIN 15M is a clear colourless solution. 4. CLINCAL PARTICUALRS 4.1 Therapeutic indications PROSTIN 15M is indicated for the treatment of postpartum haemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of PROSTIN 15M has resulted in satisfactory control of haemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered embolic agents have contributed to the outcome. In a high proportion of cases, PROSTIN 15M used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention. 4.2 Dose and method of administration Dose An initial dose of 250 µg (1 mL) is to be given by deep intramuscular injection. In clinical trials, it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome. The need for additional injections and the interval at which these should be given can be determined only by the attending physicians as dictated by the course of clinical events.
    [Show full text]
  • Oxytocin Carbetocin
    CARBETOCIN To prevent life-threatening pregnanCy CompliCations Postpartum haemorrhage (PPH) is commonly defined as a blood loss of at least 500 ml within 24 hours after birth, and affects about 5% of all women giving birth around the world. Globally, nearly one quarter of all maternal deaths are associated with PPH, and in most low-income countries it is the main cause of maternal mortality. The use of good quality prophylactic uterotonics can avoid the majority of PPH-associated complications during the third stage of labor (the time between the birth of the baby and complete expulsion of the placenta). In settings where oxytocin is unavailable or its quality cannot be guaranteed, the use of other injectable uterotonics (carbetocin, or if appropriate ergometrine/methylergometrine, or oxytocin and ergometrine fixed-dose combination) or oral misoprostol is recommended for the prevention of PPH. The use of carbetocin (100 μg, IM/IV) is recommended for the prevention of PPH for all births in contexts where its cost is comparable to other effective uterotonics. Carbetocin is only recommended for the prevention of postpartum hemorrhage and not recommended for other obstetric indications, such as labor induction, labor augmentation or treatment of PPH. OXYTOCIN Mode of Action CARBETOCIN Synthetic cyclic peptide form of the Long-acting synthetic analogue of naturally occurring posterior oxytocin with agonist properties. pituitary hormone. Binds to oxytocin Binds to oxytocin receptors in the receptors in the uterine myometrium, uterine smooth muscle, resulting in stimulating contraction of this rhythmic contractions, increased uterine smooth muscle by increasing frequency of existing contractions, the sodium permeability of uterine and increased uterine tone.
    [Show full text]
  • Eicosanoids & Platelet Activating Factor
    Eicosanoids & Platelet Activating Factor Prof. Sanjay Khattri Dept. of Pharmacology & Therapeutics King George’s Medical University, Lucknow 1 Autacoid These are the substances produced by wide variety of cells that act locally at the site of production. (local hormones) 2 Mediators of Inflammation and Immune reaction 1. Vasoactive amines (Histamine and Serotonin) 2.Eicosanoids 3.Platlet Activating Factor 4.Bradykinins 4.Nitric Oxide 5.Neuropeptides 6.Cytokinines 3 EICOSANOIDS PGs, TXs and LTs are all derived from eicosa (referring to 20 C atoms) tri/tetra/ penta enoic acids. Therefore, they can be collectively called eicosanoids. Major source: 5,8,11,14 eicosa tetraenoic acid (arachidonic acid). Other eicosanoids of increasing interest are: lipoxins and resolvins. The term prostanoid encompasses both prostaglandins and thromboxanes. 4 EICOSANOIDS Contd…. In most instances, the initial and rate-limiting step in eicosanoid synthesis is the liberation of intracellular arachidonate, usually in a one-step process catalyzed by the enzyme phospholipase A2 (PLA2). PLA2 generates not only arachidonic acid but also lysoglyceryl - phosphorylcholine (lyso-PAF), the precursor of platelet activating factor (PAF). 5 EICOSANOIDS Contd…. Corticosteroids inhibit the enzyme PLA2 by inducing the production of lipocortins (annexins). The free arachidonic acid is metabolised separately (or sometimes jointly) by several pathways, including the following: Cyclo-oxygenase (COX)- Two main isoforms exist, COX-1 and COX-2 Lipoxygenases- Several subtypes, which
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH HEMABATE® STERILE SOLUTION (carboprost tromethamine injection USP) 250 µg/mL Prostaglandin Pfizer Canada Inc. Date of Revision: 17,300 Trans-Canada Highway February 21, 2014 Kirkland, Quebec H9J 2M5 Control No. 170114 ® Pfizer Enterprises SARL Pfizer Canada Inc, Licensee © Pfizer Canada Inc. 2014 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY OF PRODUCT INFORMATION ..................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................11 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................12 DOSAGE
    [Show full text]
  • Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins
    Article Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins Márton Enesei 1,2,László Takács 2, Enik˝oTormási 3, Adrienn Tóthné Rácz 3, Zita Róka 3, Mihály Kádár 3 and Zsuzsanna Kardos 2,* 1 Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, M˝uegyetemrakpart 3, 1111 Budapest, Hungary; [email protected] 2 CHINOIN, a member of Sanofi Group, PG Development, Tó utca 1-5, 1045 Budapest, Hungary; laszlo.takacs@sanofi.com 3 CHINOIN, a member of Sanofi Group, PG Analytics, Tó utca 1-5, 1045 Budapest, Hungary; robertne.tormasi@sanofi.com (E.T.); adrienn.tothneracz@sanofi.com (A.T.R.); zita.roka@sanofi.com (Z.R.); mihaly.kadar@sanofi.com (M.K.) * Correspondence: zsuzsanna.kardos@sanofi.com Received: 15 June 2020; Accepted: 10 August 2020; Published: 18 August 2020 Abstract: Four enantiomeric forms of natural prostaglandins, ent-PGF α (( )-1), ent-PGE ((+)-2) 2 − 2 ent-PGF α (( )-3), and ent-PGE ((+)-4) have been synthetized in gram scale by Corey synthesis used 1 − 1 in the prostaglandin plants of CHINOIN, Budapest. Chiral HPLC methods have been developed to separate the enantiomeric pairs. Enantiomers of natural prostaglandins can be used as analytical standards to verify the enantiopurity of synthetic prostaglandins, or as biomarkers to study oxidation processes in vivo. Keywords: preparation; ent-PGF2α; ent-PGF1α; ent-PGE2; ent-PGE1; chiral HPLC; enantiomeric separation; mirror images; enantiopurity 1. Introduction Interest in the field of prostaglandins has been steadily growing since the basic work of Bergström Samuelsson, and Vane [1–3]. Their discoveries revealed the structure, the enzyme-controlled biochemical synthesis from arachidonic acid, and the main physiological effects of prostaglandins as well as their related substances.
    [Show full text]
  • Antitumor Effects of Desmopressin in Combination with Chemotherapeutic Agents in a Mouse Model of Breast Cancer GISELLE V
    ANTICANCER RESEARCH 28 : 2607-2612 (2008) Antitumor Effects of Desmopressin in Combination with Chemotherapeutic Agents in a Mouse Model of Breast Cancer GISELLE V. RIPOLL, SANTIAGO GIRON, MARTIN J. KRZYMUSKI, GUILLERMO A. HERMO, DANIEL E. GOMEZ and DANIEL F. ALONSO Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Argentina Abstract. The vasopressin peptide analog desmopressin has cytotoxicity on tumor cells, suggesting that the compound been used during surgery to prevent bleeding in patients with modulates a complex biological mechanism on the host coagulation defects. Recent experimental and clinical data which influences tumor spread. We further demonstrated that revealed that perioperative desmopressin therapy can perioperative administration of DDAVP dramatically reduced minimize the spread and survival of residual cancer cells. lymph node and lung metastasis in a model of mammary Here, we explored the antitumor effects of desmopressin in tumor manipulation and surgical excision in mice (6). More combination with chemotherapeutic agents using the F3II recently, a veterinary clinical study showed that perioperative mammary carcinoma in syngeneic Balb/c mice. Intravenous DDAVP prolonged disease-free survival in surgically treated administration of desmopressin at a dose of 2 μg/kg together bitches with locally advanced mammary cancer (7). with weekly cycles of carmustine (20 mg/kg) prevented Breast cancer is one of the most commonly diagnosed primary tumor infiltration of the skin. Combination of malignanc ies in women and mortality for the disease is related desmopressin with paclitaxel (25 mg/kg) significantly reduced to the capacity of breast tumor cells to invade and metastasize. metastatic progression to the lung.
    [Show full text]
  • Postpartum Haemorrhage
    Guideline Postpartum Haemorrhage Immediate Actions Call for help and escalate as necessary Initiate fundal massage Focus on maternal resuscitation and identifying cause of bleeding Determine if placenta still in situ Tailor pharmacological management to causation and maternal condition (see orange box). Complete a SAS form when using carboprost. Pharmacological regimen (see flow sheet summary) Administer third stage medicines if not already done so. Administer ergometrine 0.25mg both IM and slow IV (contraindicated in hypertension) IF still bleeding: Administer tranexamic acid- 1g IV in 10mL via syringe driver set at 1mL/minute administered over 10 minutes OR as a slow push over 10 minutes. Administer carboprost 250micrograms (1mL) by deep intramuscular injection Administer loperamide 4mg PO to minimise the side-effect of diarrhoea Administer antiemetic ondansetron 4mg IV, if not already given Prophylaxis Once bleeding is controlled, administer misoprostol 600microg buccal and initiate an infusion of oxytocin 40IU in 1L Hartmann’s at a rate of 250mL/hr for 4 hours. Flow chart for management of PPH Carboprost Bakri Balloon Medicines Guide Ongoing postnatal management after a major PPH 1. Purpose This document outlines the guideline details for managing primary postpartum haemorrhage at the Women’s. Where processes differ between campuses, those that refer to the Sandringham campus are differentiated by pink italic text or have the heading Sandringham campus. For guidance on postnatal observations and care after a major PPH, please refer to the procedure ‘Postpartum Haemorrhage - Immediate and On-going Postnatal Care after Major PPH 2. Definitions Primary postpartum haemorrhage (PPH) is traditionally defined as blood loss greater than or equal to 500 mL, within 24 hours of the birth of a baby (1).
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • The Oxytocin Receptor Gene (OXTR) Is Associated with Autism Spectrum Disorder: a Meta-Analysis
    Molecular Psychiatry (2015) 20, 640–646 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: a meta-analysis D LoParo and ID Waldman The oxytocin receptor gene (OXTR) has been studied as a risk factor for autism spectrum disorder (ASD) owing to converging evidence from multiple levels of analysis that oxytocin (OXT) has an important role in the regulation of affiliative behavior and social bonding in both nonhuman mammals and humans. Inconsistency in the effect sizes of the OXTR variants included in association studies render it unclear whether OXTR is truly associated with ASD, and, if so, which OXTR single-nucleotide polymorphisms (SNPs) are associated. Thus, a meta-analytic review of extant studies is needed to determine whether OXTR shows association with ASD, and to elucidate which specific SNPs have a significant effect on ASD. The current meta-analysis of 16 OXTR SNPs included 3941 individuals with ASD from 11 independent samples, although analyses of each individual SNP included a subset of this total. We found significant associations between ASD and the SNPs rs7632287, rs237887, rs2268491 and rs2254298. OXTR was also significantly associated with ASD in a gene-based test. The current meta-analysis is the largest and most comprehensive investigation of the association of OXTR with ASD and the findings suggest directions for future studies of the etiology of ASD. Molecular Psychiatry (2015) 20, 640–646; doi:10.1038/mp.2014.77; published online 5 August 2014 INTRODUCTION sizes.8 Nevertheless, several genes and genomic regions have Autism spectrum disorder (ASD) refers to a group of neuro- shown relatively consistent association with ASD.
    [Show full text]